FIGURE 1.

The expression and clinical characteristics of MTHFD2 in LUAD. A, Expression profiles of enzymes that involved in cytoplasmic and mitochondrial one‐carbon metabolism pathways based on TCGA LUAD samples using UCSC Xena. B, The relative mRNA expression levels of MTHFD2 in Selamat LUAD samples compared with normal lung tissues from Oncomine Database. C, The relative mRNA levels of MTHFD2 in 21 paired normal lung and tumour tissues from LUAD patients. D and E, The representative IHC staining and scores of MTHFD2 in 21 paired normal lung and tumour tissues from LUAD patients. Scale bar, 50 μm. F, G and H, Differential expression of MTHFD2 based on patient's gender, individual cancer stages, patient's smoking habits in LUAD patients from TCGA database using UALCAN. I, Prognostic analysis for overall survival (OS) of LUAD patients stratified by MTHFD2 expression level using Kaplan‐Meier plotter. *P < .05, **P < .01, ***P < .001